Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Analysis and Forecast by Size, Share, Growth, Trends 2031
Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Service Type (Drug Development and Manufacturing, Testing and Regulatory Services, and Other Service Types), Product Type (Gene Therapy and Cell Therapy), and End User (Pharmaceutical Companies, Biopharmaceutical Companies, and Other End Users)
- Status : Published
- Report Code : TIPRE00043120
- Category : Life Sciences
- No. of Pages : 174
- Available Report Formats :
The Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market size is expected to reach US$ 434.1 Million by 2031 from US$ 90.3 Million in 2024. The market is estimated to record a CAGR of 25.3% from 2025 to 2031.
Executive Summary and Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Analysis:The cell and gene therapy contract development and manufacturing organization market in the Middle East & Africa is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The market growth is driven by a combination of increasing healthcare investments, rising prevalence of chronic and genetic diseases, and growing interest in advanced therapeutic modalities. Governments in countries such as the UAE and Saudi Arabia are actively investing in biotechnology and life sciences as part of broader economic diversification strategies, like Saudi Vision 2030. These initiatives aim to reduce reliance on oil revenues by fostering innovation-driven sectors, including biotechnology and personalized medicine. As a result, there is a growing demand for local and regional expertise in the development and manufacturing of complex therapies like cell and gene therapies. Additionally, many organizations are increasingly investing in improving the manufacturing capabilities of cell and gene therapy. Academic and research institutions are also becoming more active in cell and gene therapy RandD, often collaborating with CDMOs to bridge the gap between discovery and commercialization.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- By Service Type, the Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Drug Development and Manufacturing, Testing and Regulatory Services, and Others. Drug Development and Manufacturing held the largest share of the market in 2024.
- By Product Type, the Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Gene Therapy and Cell Therapy. Gene Therapy held the largest share of the market in 2024.
- By End User, the Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Pharmaceutical Companies, Biopharmaceutical Companies, and Others. Biopharmaceutical Companies held the largest share of the market in 2024.
The integration of AI, machine learning, and other digital technologies into manufacturing and production processes allows CDMOs to streamline operations, optimize efficiency, reduce costs, and maintain compliance with regulatory standards. With increasing complexities in cell and gene therapies, the use of these technologies is proving essential to meet the growing demand for scalable solutions and high-quality. AI and digital tools are revolutionizing various aspects of gene therapy manufacturing. For instance, in February 2025, NecstGen and Digi.Bio, collaborated to improve testing and development for Cell Therapies. This partnership utilises Digi.Bio's cutting-edge platform to deliver dynamic multiparametric single-cell immunoprofiling, aiming to accelerate the journey from concept to therapeutic. The increasing application of AI in process optimization and predictive analytics is expected to emerge as a major trend in the coming years. Machine learning algorithms are being used to monitor real-time data from temperature, pH levels, and cell viability to predict potential failures or deviations before actual occurrence. This predictive capability enables CDMOs to take corrective actions proactively, reducing downtime and improving the quality and yield of therapeutic products. For instance, in October 2024, OmniaBio opened its new commercial-ready manufacturing facility and AI centre of excellence in Hamilton, Ontario, Canada. At 100,000 sq. ft., It is one of the largest CDMO dedicated to cell and gene therapy. Similarly, in August 2024, Researchers at the Broad Institute of MIT and Harvard have developed a machine-learning approach that promises to speed up AAV engineering for gene therapy.
Traditional cell culture techniques for gene therapies are labor-intensive and time-consuming, often requiring constant monitoring. However, AI-based systems can automate aspects of this process, including cell growth monitoring, optimizing nutrient delivery, and adjusting environmental conditions. This automation speeds up production timelines and reduces human error, which is crucial in gene therapy where precision is key. For instance, BioMarin Pharmaceutical has implemented AI systems to automate cell culture monitoring in their gene therapy production processes, resulting in improvements in productivity and scalability.
Gene therapy manufacturing involves vast amounts of data that must be recorded and analyzed for regulatory purposes. AI and digital tools enable seamless data integration, ensuring that all necessary documentation is complete and accurate for regulatory review. This integration is important as the FDA and EMA continue to maintain the stringent standards for gene therapy manufacturing. CDMOs that leverage AI and digital platforms can better manage the complexities of regulatory submissions and ensure compliance with evolving standards.
Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Country InsightsBy country, the Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market is segmented into Saudi Arabia, South Africa, the United Arab Emirates, and the Rest of Middle East & Africa. South Africa held the largest share in 2024.
South Africa's established pharmaceutical industry, exemplified by companies such as Aspen Pharmacare, provides a strong foundation for the growth of CDMO services in the cell and gene therapy sector. Aspen's extensive experience in manufacturing biologics and active pharmaceutical ingredients positions it as a potential leader in the contract manufacturing space for advanced therapies. The company's existing infrastructure and expertise can be leveraged to support the production of cell and gene therapies, meeting both local and international demands.
According to the article Rare is everywhere : Embracing rare disease in South Africa, published by Illumina in February 2022, more than 4.1 million individuals in South Africa were living with a rare disease, and one in 15 people will contract a rare disease in the country at some point in their lives. These conditions underscore the necessity for advanced therapeutic solutions, including gene therapies. CDMOs play a significant role in advancing the treatment of rare diseases through innovations in cell and gene therapies by providing specialized manufacturing infrastructure, regulatory support, and clinical trial services to companies. In conclusion, the combination of a strong pharmaceutical industry, growing disease prevalence, and supportive government policies favors South Africa's growth in cell and gene therapy CDMO landscape.
Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Company ProfilesSome of the key players operating in the market include Charles River Laboratories International Inc, Catalent Inc, Lonza Group AG, WuXi Biologics Inc, Pluri Inc, Aenova Holding GmbH, Takara Bio Inc, FUJIFILM Holdings Corp, AGC Biologics AS, Thermo Fisher Scientific Inc., Minaris Advanced Therapies, and SK pharmteco Inc
These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Research MethodologyThe following methodology has been followed for the collection and analysis of data presented in this report:
Secondary Research
The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
- Company websites, annual reports, financial statements, broker analyses, and investor presentations
- Industry trade journals and other relevant publications
- Government documents, statistical databases, and market reports
- News articles, press releases, and webcasts specific to companies operating in the market
Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.
Primary Research
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:
- Validate and refine findings from secondary research
- Enhance the expertise and market understanding of the analysis team
- Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
- Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
- External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. Cell and Gene Therapy Contract Development and Manufacturing Organization Market Landscape
4.2 PEST Analysis
5. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Middle East & Africa Market Analysis
6.1 Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue (US$ Million), 2024 - 2031
6.2 Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Forecast and Analysis
7. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue Analysis - by Service Type
7.1 Drug Development and Manufacturing
7.1.1 Overview
7.1.2 Drug Development and Manufacturing: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Testing and Regulatory Services
7.2.1 Overview
7.2.2 Testing and Regulatory Services: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.3 Others
7.3.1 Overview
7.3.2 Others: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue Analysis - by Product Type
8.1 Gene Therapy
8.1.1 Overview
8.1.2 Gene Therapy: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Cell Therapy
8.2.1 Overview
8.2.2 Cell Therapy: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue Analysis - by End User
9.1 Pharmaceutical Companies
9.1.1 Overview
9.1.2 Pharmaceutical Companies: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Biopharmaceutical Companies
9.2.1 Overview
9.2.2 Biopharmaceutical Companies: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Country Analysis
10.1 Middle East & Africa
10.1.1 Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue and Forecast and Analysis - by Country
10.1.1.1 Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue and Forecast and Analysis - by Country
10.1.2.2 Saudi Arabia: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.1.2.2.1 Saudi Arabia: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.1.2.2.2 Saudi Arabia: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.1.2.2.3 Saudi Arabia: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
10.2.3.3 South Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2.3.3.1 South Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.2.3.3.2 South Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.2.3.3.3 South Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
10.3.4.4 United Arab Emirates: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3.4.4.1 United Arab Emirates: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.3.4.4.2 United Arab Emirates: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.3.4.4.3 United Arab Emirates: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
10.4.5.5 Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4.5.5.1 Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.4.5.5.2 Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.4.5.5.3 Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
11 Competitive Landscape
11.2 Global Company Market Share Analysis, 2024
12 Industry Landscape
12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments
13 COMPANY PROFILES
13.1 Charles River Laboratories International Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Catalent Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Lonza Group AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 WuXi Biologics Inc
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Pluri Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Aenova Holding GmbH
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Takara Bio Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 FUJIFILM Holdings Corp
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 AGC Biologics AS
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Thermo Fisher Scientific Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Minaris Advanced Therapies
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
13.12 SK pharmteco Inc
13.12.1 Key Facts
13.12.2 Business Description
13.12.3 Products and Services
13.12.4 Financial Overview
13.12.5 SWOT Analysis
13.12.6 Key Developments
14. Appendix
14.1 About The Insight Partners
List of Tables
Table 1. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Segmentation
Table 3. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 5. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 6. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 7. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 8. Saudi Arabia: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 9. Saudi Arabia: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 10. Saudi Arabia: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 11. South Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 12. South Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 13. South Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 14. United Arab Emirates: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 15. United Arab Emirates: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 16. United Arab Emirates: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 17. Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 18. Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 19. Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
List of Figures
Figure 1. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Key Market Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue (US$ Million), 2024 - 2031
Figure 6. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share (%) - by Service Type, 2024 and 2031
Figure 7. Drug Development and Manufacturing: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 8. Testing and Regulatory Services: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Others: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share (%) - by Product Type, 2024 and 2031
Figure 11. Gene Therapy: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Cell Therapy: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share (%) - by End User, 2024 and 2031
Figure 14. Pharmaceutical Companies: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Biopharmaceutical Companies: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Others: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 18. Saudi Arabia: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. South Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. United Arab Emirates: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Global Company Market Share Analysis, 2024
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For